Company intelligence
ALX Oncology
ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boosting the immune system.
Biotechnology Research
South San Francisco, US
64 employees
Founded 2015
1 public signals
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
Verified activity
Signals from ALX Oncology
1 published signal